Skip to Main Content
Table 1

Baseline characteristics of people who never versus ever achieved NGR during DPP

Never NGR (sample size 2,181)Ever NGR (sample size 1,053)P
Race    
 White 1,206 (55) 562 (53) 0.0017 
 Black 437 (20) 208 (20)  
 Hispanic 346 (16) 162 (15)  
 Asian 101 (5) 41 (4)  
 American Indian 91 (4) 80 (8)  
Sex    
 Male 714 (33) 329 (31) 0.3946 
 Female 1,467 (67) 724 (69)  
Medical history at baseline DPP    
 Hypertension* 496 (23) 183 (17) 0.0006 
 Dyslipidemia 793 (36) 345 (27) 0.0448 
 Hormone-replacement use 521 (24) 239 (27) 0.4541 
 Age 51.1 ± 10.8 49.7 ± 10.5 0.0004 
 Baseline A1C (%) 5.96 ± 0.51 5.81 ± 0.47 <0.0001 
 Average A1C during follow-up 6.10 ± 0.70 5.76 ± 0.49 <0.0001 
 Aspirin (frequency/week) 1.92 ± 1.55 1.90 ± 1.49 0.7371 
Never NGR (sample size 2,181)Ever NGR (sample size 1,053)P
Race    
 White 1,206 (55) 562 (53) 0.0017 
 Black 437 (20) 208 (20)  
 Hispanic 346 (16) 162 (15)  
 Asian 101 (5) 41 (4)  
 American Indian 91 (4) 80 (8)  
Sex    
 Male 714 (33) 329 (31) 0.3946 
 Female 1,467 (67) 724 (69)  
Medical history at baseline DPP    
 Hypertension* 496 (23) 183 (17) 0.0006 
 Dyslipidemia 793 (36) 345 (27) 0.0448 
 Hormone-replacement use 521 (24) 239 (27) 0.4541 
 Age 51.1 ± 10.8 49.7 ± 10.5 0.0004 
 Baseline A1C (%) 5.96 ± 0.51 5.81 ± 0.47 <0.0001 
 Average A1C during follow-up 6.10 ± 0.70 5.76 ± 0.49 <0.0001 
 Aspirin (frequency/week) 1.92 ± 1.55 1.90 ± 1.49 0.7371 

Data are n (%) or means ± SD.

*Hypertension defined as being on a blood pressure–lowering medication, systolic blood pressure ≥140 mmHg, and/or diastolic blood pressure ≥90 mmHg.

Close Modal

or Create an Account

Close Modal
Close Modal